#Sinopharm

[agreenroad]

What If Pfizer Is Chinese Government Controlled? BioNTech Signed MOU With Fosun Pharma - How Many Chinese/US High Tech Connections To Covid 19 Virus And Vaccine?

BioNTech, the subsidiary that manufactures Pfizer’s injections signed a memorandum of understanding with Fosun Pharma Dr. Naomi Wolf: Pfizer is essentially a company controlled by the Chinese government! ‼️ BioNTech, the subsidiary that manufactures Pfizer's injections, has signed a memorandum of understanding with Fosun Pharma, one of China's largest CCP-controlledpic.twitter.com/vJnqq0FpZU—…

[etsyee]

Sinopharm Budapest T-Shirt

Express yourself with ease with Sinopharm Budapest T-Shirt, sinopharm Budapest t-shirts are a symbol of resilience and unity in the face of adversity. These t-shirts not only represent a clothing item, but also carry a strong message of hope and determination. The Sinopharm Budapest t-shirt has become a popular item in recent times, particularly during the current global pandemic.

Buy now: Sinopharm Budapest T-Shirt

More Post:

Slainte Irish Drink Shirt

You’re Telling Me A Dick Sported These Goods T-Shirt

Visit Store: https://etsyee.com/

[allthebrazilianpolitics]

Brazilian-developed vaccine against Covid-19 registered by Anvisa

The new vaccine against Covid-19 developed by the Brazilian company Zalika Farmacêutica has been entered into the National Health Surveillance Agency (Anvisa) this week, Agencia Brasil reported. The drug can be used in people aged 12 and over and is to be administered in two doses, 21 days apart, with boosters after 6 months for those over 18 years of age.

The technology used in the Zalika vaccine is called “recombinant” because its molecules are formed by combining two different sources. In this case, the protein S antigen (spike) -capable of promoting a response from the immune system- and the saponin-based adjuvant allow the mixture to enhance the production of antibodies. This form of production brings greater safety to the pharmaceutical industry, Anvisa explained in a statement.

The new immunizer is the sixth to receive definitive individual registration from Anvisa, in addition to Comirnaty Ipfizer/Wyeth, Comirnaty bivalent (Pfizer), Janssen Vaccine (Janssen-Cila), Oxford/Covishield (Fiocruz and Astra-Zeneca) and Spikevax bivalent vaccines have received this type of authorization. Pfizer/Biontech, Astra-Zeneca, Janssen, Moderna, Sinopharm, and Sinovac also have definitive registration in the form of the Covax Facility consortium.

Continue reading.

[nice2meetyouu]

Hindi na Palamunin 2023

These days, nags-stay kami ng kapatid ko sa ibang lugar kasi walang tubig sa bahay. Ang saya, ang payapa!!! Ayaw nga umuwi ng kapatid ko kasi walang tubig, pero sabi ng nanay ko, "Bakit? Kasi wala ako?" Or something similar.

Dito, para makapaghugas ng pinggan, nag-iigib sa timba ng tubig tapos inaakyat sa third floor. Tapos kailangan, tipid na tipid sa pagbuhos. Mahirap din mag-toothbrush at mag-CR. Tatay ko lang ang naliligo (kasi siya lang masipag magbuhat ng tubig paakyat).

Anyway, ang irrelevant ng intro pero tungkol lang naman talaga 'to sa may trabaho na ako. Tinawagan ako last week habang nasa bank para i-congratulate. Ang company na ito ay isa sa mga gumawa ng COVID vaccine noong pandemic. Sabi ng parents ko noong sinabi ko sa kanila at ganyan din ang description ko, "Sinovac? Sinopharm? O 'yung bakuna galing sa India?" Aguy.

Dahil bibo-bibo ako este gusto ko na rin magstart agad para may sahod agad, next week na ako magsisimula. Kaya lang, inunderestimate ko 'yung hirap ng paperwork. Bukod sa usual pre-employment requirements, may sangkatutak silang forms. Pinapasulat pa ako ng commitment letter.

Ang higpit ah, may pa-background check-background check pang nalalaman. Ano kayang makikita nila roon? Ang daya eh, positive or negative lang marereceive ko. Pag negative, tsugi na ako, kahit pa "hired" na.

Buti kung gano'n lang, kaso may bond 'yung kontrata, so bawal ako umalis for X years. Pag daw umalis ako in less than X years, magbabayad ako ng Y amount (note: 5 digits, mataas) at kasama sa inilagay nilang reason eh nag-spend sila ng effort sa hiring process. Aba, ako rin naman ah!

Yay to corporate slavery! Abangan kung happy pa ako sa 2024.

[todayworldnews2k21]

Mpox vaccine ready for clinical trial

China’s top drug regulator has recently approved clinical trials of a mpox vaccine developed by the domestic drugmaker Sinopharm, adding to a growing number of homegrown candidates in the pipeline, according to the company. The experimental vaccine is jointly created by the Beijing Institute of Biological Products administered by Sinopharm as well as the National Institute for Viral Disease…

[myrawjcsmicasereports]

Rapid progression of angioimmunoblastic t cell lymphoma after Covid-19 vaccination by Iryna Abramenko, MD in Journal of Clinical Case Reports Medical Images and Health Sciences

Abstract

We present the case of a 57-year-old male patient from Ukraine who developed tonsillitis and generalized lymphadenopathy approximately one week after receiving the first dose of the ChAdOx1 (AstraZeneca) anti-SARS-CoV-2 vaccine. A total body computerized tomography scan revealed pronounced lymphadenopathy above and below the diaphragm, and enlargement of the spleen. Histologic examination of the left inguinal lymph node revealed revealed lack of a clear separation of the cortical and paracortical areas. Expanded proliferation of vessels (postcapillary venules) around which atypical lymphoid cells of small and medium size were located. The most of atypical lymphoid cells expressed CD3, CD4, PD1, blc-6, and Ki-67 antigens, some cells also CD10-, CD30-positive. Diagnosis of angioimmunoblastic T-cell lymphoma (AITL), IVB Ann Arbor stage, was established. The patient received six courses of therapy CHOEP regimen. According to the results of treatment clinical and hematological remission is achieved. Thus, this article describes the second case of the development of AITL after vaccination. The accumulation of such data and their analysis will allow to make appropriate conclusions about the relationship of anti-SARS-CoV-2 vaccination with development of oncohematological diseases.

Introduction

SARS-Cov-2 virus infection is widespread throughout the world. By May 2023, the number of infected cases raised to 765,903,278 persons and a total 13,350,530,518 vaccine doses have been administered [1]. Vaccination is an effective mean of preventing infection and the development of severe forms of the disease. Eleven vaccines were recommended by World Health Organization for vaccination: Pfizer-BioNTech, Oxford-AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, CovoVax (Novavax formulation), Convidecia, Sanofi-GSK; a number of vaccines are under consideration [2]. Oxford-AstraZeneca, CoronaVac, Pfizer-BioNTech, and Moderna were used for vaccination against SARS-CoV-2 in Ukraine [3].

Vaccination leads to the development of protective antiviral immunity [4, 5]. In oncological patients, this may have ambivalent influence on tumor growth. Two cases of spontaneous tumor regression after SARS-Cov-2 vaccination have been described: shrinking of the cervical lymph node and resolution of the diffuse lung lesions in patient with a recurrent primary cutaneous anaplastic large-cell lymphoma one week after having received the first COVID-19 vaccination (BioNTech/Pfizer) [6]; and spontaneous regression of metastatic salivary gland myoepithelial carcinoma in patient one month after vaccination of mRNA-1273 COVID-19 (Moderna) vaccine [7]. Anti-cancer effect of COVID-19 vaccines (a decrease in tumor size, a decrease in the expression of tumor markers (VEGF, Ki-67, MMP-2/9), CD4/CD8 ratio, and metastasis to the vital organs) has been shown in 4T1 mice models [8].

On the other hand, cases of progression of oncohematological diseases after vaccination have also been described. Goldman et al. described rapid progression of angioimmunoblastic T cell lymphoma following BNT162b2 mRNA vaccine booster shot [9]. Cavanna et al. presented a case of anaplastic large-cell lymphoma that developed in a patient approximately 10 days after receiving the third dose of the BNT162b2 vaccine and summarized eight additional cases identified in the available literature [10]. There were four cases of diffuse large-B-cell lymphoma [11-13], one case of extranodal NK/T-cell lymphoma [12], one patient with subcutaneous panniculitis-like T-cell lymphoma [14], one case of marginal zone B-cell lymphoma [15] and one primary cutaneous anaplastic large-cell lymphoma  (developed at the SARS-CoV2 vaccine injection site) [16].

In this article, we report a case of angioimmunoblastic T-cell lymphoma developed shortly after SARS-CoV2 vaccination.

Case report

The patient is a 57-year-old Caucasian man with no previous history of disease. On May 6, 2021, he received the first dose of the ChAdOx1 (AstraZeneca). A few days later, he noted a flu-like syndrome and a sore throat. A diagnosis of tonsillitis was established. Antibacterial therapy was ineffective and within two weeks patient noted rapid increase of cervical, axillary, and inguinal lymph nodes. On May, 28, 2021, trephine biopsy of the left inguinal lymph node was performed.

Pathological examination revealed lack of a clear separation of the cortical and paracortical areas. Expanded proliferation of vessels (postcapillary venules) around which atypical lymphoid cells of small and medium size were located. Mitotic figures, single plasma cells, macrophages, neutrophils and eosinophils were present. The most of atypical lymphoid cells expressed CD3, CD4, PD1, blc-6, and Ki-67 antigens, some cells also CD10-, CD30-positive. Small clusters of CD20-positive cells were found between tumor cells. CD21- and CD23-positive follicular dendritic cells wrapped around postcapillary venules. Conclusion (8.06.2021): morphological changes in the lymph node and the immunophenotype of tumor cells correspond to diagnosis of angioimmunoblastic T cell lymphoma.

CT scan (29.05.2021) revealed pronounced lymphadenopathy above and below the diaphragm (diameters of cervical lymph nodes 10-24 mm, paratracheal lymph nodes 8-18 mm, bifurcation lymph nodes 14-25 mm, right axillary lymph nodes up to 20 mm, left axillary lymph nodes up to 15 mm, inguinal lymph nodes 8-28 mm), enlargement of the spleen (5.8x12.0x11.3 cm).

On June, 11, 2021 patient referred to the hematological department of National Research Center for Radiation Medicine. Complaints of the patient upon admission: fever (up to 380C) in the second half of the day, weakness, severe fatigue, enlargement of tonsils and lymph nodes. At examination: ECOG2 performance status. Weight 72 kg. Height 174 cm. Skin is pale. Peripheral lymph nodes are palpable: submaxillary up to 6 cm, cervical 4-6 cm, axillary up to 4 cm, inguinal up to 4 cm in diameter. The liver is not enlarged. The spleen is not palpable. Breathing is vesicular. Systolic murmur over the cardiac apex. The heart rhythm is correct. Blood pressure is 115/75 mm Hg, heart rate is 80 per min. There are no edema.

Bone marrow aspiration (11.06.2021) showed hypercellular marrow, dysplasia in erythropoiesis and megakariocytopoiesis, absence of blast cells, 5.6% of lymphocytes, no cytological signs of leukemic involvement. Among all nuclear bone marrow cells 1.68% with phenotype CD45dim+CD34+CD7+CD5+CD1a-TdT- were quantified by flow cytometry.

Except high level of blood lactate dehydrogenase (1249 units/L), and C-reactive protein (29.8 mg|L) other results of laboratory test of blood and urine were unremarkable.

Diagnosis of angioimmunoblastic T-cell lymphoma (AITL), IVB Ann Arbor stage, was established, and CHOEP (cyclophosphamide, vincristine, doxorubicin, etoposide and prednisone) regimen was initiated. The patient received six courses of therapy CHOEP regimen. According to the results of treatment clinical and hematological remission is achieved: hemodynamic parameters are stable, peripheral lymph nodes are not palpable, the spleen is not enlarged, and the size of the tonsils has decreased significantly.  At the time of this report the patient continues to be in clinical and hematological remission.

Discussion

The most exciting, intriguing question is: can vaccines induce the development of tumors, in particular, lymphoproliferative diseases?

So far, only the development of fibrosarcomas in cats after vaccination is known. This has been proven for killed adjuvanted virus vaccines (vaccination against rabies and feline leukemia virus). An inflammatory process with the formation of granulomatous nodules, only 5% of which subsequently undergo transformation, preceded tumor development. The interval between vaccine administration and detection of sarcoma varied from 4 months to several years [17]. In human, we found three similar cases in the literature: the development of lymphoma and undifferentiated, pleiomorphic high-grade sarcoma at the site of anti-SARS-CoV-2 vaccine administration [16, 18], and peripheral T-cell lymphoma at the injection site of influenza vaccination [19]. However, the interval between vaccine administration and tumor development was short, which does not fit into the classical scheme for the development of the oncological process (initiation, promotion, progression). Thus, it is unclear whether there is a true association between vaccination and the development of malignancy.

For the case described in this article, progression of preceding lymphoma under the influence of the vaccine seems more likely. Anti-SARS-CoV-2 vaccines cause a powerful immune response and stimulation of T- and B-lymphocytes, as well as the production of numerous cytokines [20]. Cases of post vaccine benign lymphadenopathy are described [21]. Today, AITL is recognized as a neoplasm derived from T-follicular helper cells [22, 23]. Up to 75% of AITL patients had a mutation RHOA G17V that facilitates proliferation and activation of several signaling pathways [24]. Since T-follicular helper cells are one of the main targets of mRNA vaccines [25], the Goldman et al. suggested that their stimulation under the influence of the vaccine can accelerate the development of AITL. In their case the malignant cells of patient had a mutation RHOA G17V that could make them especially sensitive to anti-SARS-CoV-2 vaccines [9]. Unfortunately, molecular genetic studies have not been performed in our patient.

Thus, this article describes the second case of the development of AITL after vaccination. The accumulation of such data and their analysis will allow to make appropriate conclusions about the relationship of anti-SARS-CoV-2 vaccination with development of oncohematological diseases. It will contribute to our better understanding of the possible negative consequences of anti-SARS-CoV-2 vaccination and their prevention as well.

[darkmaga-returns]

Children’s Health Defense’s The Defender has a blockbuster report. (link in footnote)

“A group of Argentine scientists identified 55 chemical elements—not listed on package inserts—in the Pfizer, Moderna, AstraZeneca, CanSino, Sinopharm and Sputnik V COVID-19 vaccines, according to a study published last week in the International Journal of Vaccine Theory, Practice, and Research.”

“The chemical elements include 11 heavy metals—such as chromium, arsenic, nickel, aluminum, cobalt and copper—which scientists consider systemic toxicants known to be carcinogenic and to induce organ damage, even at low exposure levels.”

ARSENIC in the vaccines? How does that happen? I can’t see how a vaccine assembly line would be accidentally contaminated with arsenic, from other prior uses.

There are extremely important further statements in the Defender article. For example:

“The research builds on a series of studies conducted since 2021 using different analytic techniques to analyze COVID-19 vaccine vials from major manufacturers. Previous studies also identified significant numbers of chemical elements not listed on vaccine labels.”

“Research efforts included a 2022 study by a German working group, including the late pathologist Arne Burkhardt, submitted to the German government; a 2021 study by scientists in England; a 2022 study by Canadian Dr. Daniel Nagase; and a 2023 Romanian study by Dr. Geanina Hagimă.”

These previous studies, which yielded results similar to the findings of the latest Argentine group, flew under the radar.

There is no doubt that toxic chemicals in COVID vaccines is an URGENT issue which needs to be widely known and investigated further—after the vaccinations are halted immediately.

Of course, for a number of reasons I and others have explained for years, the vaccines should never have been launched in the first place.

Warp Speed was one of Trump’s gross exaggerations. It was a lethal project from the beginning. Trump would prefer it to be buried as ancient history. He still claims the kill shot “saved millions of lives.”

Trump’s interim President—he stood aside and let Fauci run the country—eventually made sure the vaccine was mandated.

[saadkhan2917]

Laboratory Reagents Market Report 2024 - By Size, Report, Growth, Demand, Forecast To 2034

 The Laboratory Reagents market report offered by Reports Intellect is meant to serve as a helpful means to evaluate the market together with an exhaustive scrutiny and crystal-clear statistics linked to this market. The report consists of the drivers and restraints of the Laboratory Reagents Market accompanied by their impact on the demand over the forecast period. Additionally, the report includes the study of prospects available in the market on a global level. With tables and figures helping evaluate the Global Laboratory Reagents market, this research offers key statistics on the state of the industry and is a beneficial source of guidance and direction for companies and entities interested in the market. This report comes along with an additional Excel data-sheet suite taking quantitative data from all numeric forecasts offered in the study.

Get Sample PDF Brochure @ https://www.reportsintellect.com/sample-request/2910555

Key players offered in the market: Merck Thermo TCI American Element Sinopharm Xilongchemical ABCR BOC Sciences Wako-chem Kanto Scientific OEM Glentham Life Sciences

Additionally, it takes account of the prominent players of the Laboratory Reagents market with insights including market share, product specifications, key strategies, contact details, and company profiles. Similarly, the report involves the market computed CAGR of the market created on previous records regarding the market and existing market trends accompanied by future developments. It also divulges the future impact of enforcing regulations and policies on the expansion of the Laboratory Reagents Market.

Scope and Segmentation of the Laboratory Reagents Market

The estimates for all segments including type and application/end-user have been provided on a regional basis for the forecast period from 2024 to 2034. We have applied a mix of bottom-up and top-down methods for market estimation, analyzing the crucial regional markets, dynamics, and trends for numerous applications. Moreover, the fastest & slowest growing market segments are pointed out in the study to give out significant insights into each core element of the market.

Laboratory Reagents Market Type Coverage: - Solvents Acids Standards Dyes Solutions

Laboratory Reagents Market Application Coverage: - Government Academic Industry Pharma Environmental institutions

Regional Analysis:

North America Country (United States, Canada) South America Asia Country (China, Japan, India, Korea) Europe Country (Germany, UK, France, Italy) Other Countries (Middle East, Africa, GCC)

Also, Get an updated forecast from 2024 to 2034.

Discount PDF Brochure @ https://www.reportsintellect.com/discount-request/2910555

The comprehensive report provides:

Complete assessment of all opportunities and threats in the global market.

Laboratory Reagents Market recent advancements and major events.

A thorough study of business policies for the growth of the Laboratory Reagents Market leading players.

Concluding study about the growth plot of Laboratory Reagents Market for upcoming years.

Detailed understanding of Laboratory Reagents Market particular drivers, restraints, and major micro markets.

Favorable impression inside vital technological and market latest trends hitting the Laboratory Reagents Market.

Reasons to Purchase Laboratory Reagents Market Research Report

Develop a competitive approach based on the competitive landscape

Build business strategy by identifying the high growth and attractive Laboratory Reagents market classifications

Identify potential business partners, gaining targets and business buyers

Design financial investment policies based on estimated high potential segments

Prepare management and tactical presentations using the Laboratory Reagents market data

Plan for new product promotion and portfolio in advance

Covid-19 Impact Analysis: Our research analysts are highly focused on the Laboratory Reagents Market covid-19 impact analysis. A whole chapter is dedicated to the covid-19 outbreak so that our clients get whole and sole details about the market ups & downs. With the help of our report the clients will get vast statistics as to when and where should they invest in the industry.

About Us: Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in today's competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.

Contact Us: sales@reportsintellect.com Phone No: + 1-706-996-2486 US Address: 225 Peachtree Street NE, Suite 400, Atlanta, GA 30303

[schoje]

Em entrevista coletiva transmitida hoje (15), o ministro da Saúde, Eduardo Pazuello, confirmou que o presidente Jair Bolsonaro está discutindo novos nomes para assumir a posição de titular da pasta. “O presidente está pensando em substituição, avaliando nomes. O presidente está em tratativas para reorganizar o ministério. Enquanto isso não for definido, a vida segue normal. Não estou doente. Quando o presidente tomar sua decisão faremos a transição correta, como manda o figurino”, declarou. Na coletiva em que fez um balanço da gestão no combate à pandemia, Pazuello afirmou que não deixará o ministério e que cabe ao presidente Jair Bolsonaro definir se e quando efetuará a troca de comando. “Estou à disposição para ajudar todos que vierem aqui. Isso não é palavra de despedida. Tenho orgulho de estar à frente da pasta cumprindo missão. Não me sinto pressionado por nenhuma not��cia ou fake news. O problema é a pandemia, os óbitos. Apoiar todos os brasileiros - esta é a missão”, comentou. Vacinas Em meio a críticas sobre a gestão, Pazuello fez um balanço das ações contra a pandemia, em especial os esforços de vacinação. Ele afirmou que a pasta prevê disponibilizar 562,9 milhões de doses em 2021.  Contudo, 110 milhões de doses da Oxford/AstraZeneca e 30 milhões de doses da CoronaVac previstas no cronograma e que já tiveram recursos alocados ainda não foram efetivamente contratadas, já que o dinheiro não foi pago. Assim, o número de doses efetivamente contratadas até o momento fica em 422,9 milhões. Veja abaixo o cronograma de recebimento das vacinas para o ano: IFA Pazuello afirmou que o processo de transferência de tecnologia que habilitará o Brasil a produzir o Ingrediente Farmacêutico Ativo (IFA) em território nacional está dois meses adiantado. “Já temos todos os equipamentos instalados. Os engenheiros químicos foram capacitados e devemos começar a produção em abril. Com isso, passamos a ter independência na produção de vacinas.” Mais doses A equipe do Ministério mantém também tratativas com a farmacêutica Moderna e a Sinopharm - esta ainda em estado inicial - para a compra de mais 13 milhões de doses, que não entraram na soma total apresentada pelo ministro. Programa Nacional de Imunização Pazuello informou que no fim de semana se reuniu com governadores do Nordeste e que as 37 milhões de doses compradas por eles serão custeadas pelo governo federal e distribuídas pelo Programa Nacional de Imunização. O titular do ministério apresentou uma previsão de 38 milhões de doses em março. Neste total estão oito milhões de doses da farmacêutica indiana Bharat Biotech, que ainda não obteve registro definitivo nem para uso em caráter emergencial junto à Agência Nacional de Vigilância Sanitária (Anvisa). O ministro destacou que até o final do 1º semestre o programa de vacinação terá contemplado todos os públicos prioritários, e que até 2021 ele poderá atingir a totalidade dos brasileiros, com exceção daqueles contraindicados para receber a vacina ou sem eficácia ainda comprovada em testes, como imunodeprimidos, gestantes e crianças. “Vamos vacinar até o meio do ano grupos prioritários e uma boa parte da população. Chegaremos à metade [da população]. E vamos chegar até o fim de 2021 com toda a população. Com a oferta de vacinas crescendo é provável que a velocidade aumente”, ressaltou. Assista na íntegra *Matéria atualizada para acréscimo de informações durante a coletiva.

[gamboagarcia]

Gracias de antemano por sus comentarios Se amplia a 22 millones de dosis de vacunas Chinas para México Llegarán 12 millones de Sinopharm que ha sido autorizada en 15 países. Ciudad de México - El secretario de Relaciones Exteriores (SRE), Marcelo Ebrard, informó que el Gobierno de México ha recibido confirmación para la ampliación de hasta 22 millones de dosis de vacunas contra Covid-19 de procedencia china: Sinovac y Sinopharm. Durante... Sigue leyendo: https://www.adiario.mx/orbe/se-amplia-a-22-millones-de-dosis-de-vacunas-chinas-para-mexico/?feed_id=163203&_unique_id=6689819360173

[lboogie1906]

President Évariste Ndayishimiye (born on June 17, 1968) in Giheta, Burundi. After serving in the Burundi Army, he began studies in law at the Université du Burundi in Bujumbura. His legal education was interrupted by the civil war and ethnic divisions between the Hutu and the Tutsi ethnic groups, which cost at least 300,000 lives during its thirteen years.

He married Angélique Ndayubaha Ndayishimiye (2003) an economist and the President of the Good Action Foundation “Umugiraneza.” They are the parents of six children.

He was the Interior and Public Security Minister for Burundi, he served as the personal military aide to President Pierre Nkurunziza. He received an LLB from Université Sagesse d’Afrique and chaired the Burundi National Olympic Committee. He became the Secretary-General of The National Council for the Defense of Democracy, a new Burundi political party. In 2018, he was endorsed by President Nkurunziza as his replacement after the incumbent decided not to run for a fourth term.

On June 18, 2020, he was sworn in as the 9th president of Burundi in the capital city of Gitega after winning 68 percent of the national vote in an election marred by violence and the death of Nkurunziza ten days earlier. Opposition leaders claimed the election was rigged but he vowed to “preserve and promote the country’s independence, love, and equitably achieved development. He had four journalists and two human rights defenders released from prison and announced the pardon or early release of more than 5,000 prisoners.

He addressed the UN General Assembly’s 76th session declaring that refugees who had fled the nation were welcome to return. He announced a strategic action plan designed to protect human rights in Burundi and discussed the restoration of peace, security, stability, and social cohesion in this civil war-torn nation.

In a country where the COVID-19 pandemic remains a threat to thousands of Burundi citizens, he rejected vaccines from outside the nation and closed its borders to foreigners he claimed for safety. To protect himself against COVID-19, he did receive sizable doses of the Chinese Sinopharm BIBP vaccine. #africanhistory365 #africanexcellence

[insights10-marketing]

China Anemia Therapeutics Market Analysis Report 2022 to 2030

The China Anemia Therapeutics Market is anticipated to experience a growth from $1.19 Bn in 2022 to $2.664 Bn by 2030, with a CAGR of 10.6% during the forecast period of 2022-2030. The aging population's increased risk of anemia from chronic illnesses, the burden of chronic diseases, rising disposable income that drives up healthcare expenditure, and improved awareness and early detection of anemia are the main drivers in China. The China Anemia Therapeutics Market encompasses various players across different segments, including Pfizer, Roche, GlaxoSmithKline (GSK), Novartis, Sanofi, Amgen, Jiangsu Hengrui Medicine, Guangzhou Baiyunshan Pharmaceutical, Sinopharm Group, Shanghai Pharmaceuticals, etc, among various others.

[keynewssuriname]

Volksgezondheid over AstraZeneca vaccins: Covid vaccins bieden nog steeds bescherming

Het ministerie van Volksgezondheid in Suriname heeft kennis genomen van de laatste ontwikkelingen over het besluit van het Farmaceutisch bedrijf AstraZeneca om het Covid-19 vaccin van de commerciële markt te halen. Dit komt door de grotere vraag naar nieuwere versies van Covid-19 vaccins, die zijn ontwikkeld op basis van de recentere varianten van het virus. Het bedrijf is trots op het vaccin dat het heeft ontwikkeld en waarvan wereldwijd meer dan 3 miljard doses zijn toegediend. In juni 2022 verklaarde de Wereldgezondheidsorganisatie (WHO) dat het Astra Zeneca vaccin veilig en effectief is voor personen ouder dan 18 jaar. Het Vaccin is binnen 1 jaar na de start van de pandemie ontwikkeld door wetenschappers van de Oxford University. Gedurende de vaccinatieperiode raakte het bedrijf verwikkeld in enkele rechtszaken waarbij personen claimden slachtoffer te zijn geworden van zeldzame bijwerkingen zoals bloedstolsels. Ondanks deze zeldzame bijwerkingen van bloedstolsels, wordt aangenomen dat dit vaccin miljoenen levens heeft gered. Dankzij vaccins, geproduceerd door o.a. AstraZeneca en Pfizer, is de pandemische fase van Covid-19 voorbij en zijn miljarden levens beschermd. In Suriname was AstraZeneca het eerste vaccin dat werd toegediend in februari 2021. Vermeldenswaard is dat de minister van Volksgezondheid, Amar Ramadhin, de eerste persoon in Suriname was die zich liet inenten met AstraZeneca. Daarna werden diverse vaccins, waaronder Pfizer, Sinopharm en Moderna toegediend. Het ministerie volgde de richtlijnen van de WHO en keurde alleen door de WHO erkende vaccins tegen Covid-19 goed. Het ministerie wil de gemeenschap informeren dat Covid-19 vaccins nog steeds bescherming bieden tegen ernstige gevolgen van een infectie. Momenteel is het Pfizer Covid-19 vaccin beschikbaar op aanvraag bij het BOG, de RGD en de MZ.   Read the full article